NPCE Neuropace receives FDA guidance on pma supplement for indication expansion into idiopathic generalized epilepsy

NPCE (more) Neuropace receives FDA guidance on pma supplement for indication expansion into idiopathic generalized epilepsy Neuropace - FDA requests additional clinical evidence from Nautilus trial for pma supplement - To submit submission issue request and amend pma supplement - Receives FDA notice pma supplement for ige not approvable in current form